Novartis withdraws label extension bid for Alzheimer's drugs on CHMP 'concerns'
This article was originally published in Scrip
Novartis has withdrawn its label extension application, submitted to the EMA's Committee for Medicinal Products for Human Use (CHMP), for medicines Exelon (rivastigmine) and Prometax (rivastigmine). The firm had been seeking marketing approval for the transdermal patch forms of the medicines as treatments for severe Alzheimer's dementia.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.